Draft Patents (Amendment), Rules, 2023
The Ministry of Commerce and Industry, under the Department for Promotion of Industry and Internal Trade, has introduced draft amendments to the Patents Rules, 2003. These drafts detail various changes
The Ministry of Commerce and Industry, under the Department for Promotion of Industry and Internal Trade, has introduced draft amendments to the Patents Rules, 2003. These drafts detail various changes
Courtesy earthworms, hair, weed easily converted to manure in 2003, the government ordered the closure of several hair processing units, which made wigs, in Karnataka because of pollution. Burning of hair resulted in toxic elements, which caused allergies. The problem with human hair is it takes hundreds of years to decompose (see
Joe C Mathew / New Delhi August 27, 2008, 0:39 IST Firm reaches out-of-court agreement on 5 of 19 patent challenges in the US. Ranbaxy Laboratories, India's largest pharmaceutical drug firm by sales, expects its recent patent litigation settlements to add significantly to its revenues as well as net profit. The numbers could run into billions of dollars, sources familiar with the company's strategy said. The company, in the midst of being acquired for $4.6 billion by Daiichi Sankyo, had filed 19 patent challenges in the US, but has settled five of these in the last two years.
the Drugs Controller General of India (dcgi) is preparing guidelines for linking the drug regulatory authority and the Indian patent office. The system called
P B Jayakumar / Mumbai July 29, 2008, 5:18 IST Dr Reddy's Laboratories, the country's third-biggest drugmaker, will form a joint venture with one of the world's biggest biotech companies to make biosimilars or generic versions of patented biotech drugs to take on Ranbaxy Laboratories, Reliance Life Sciences, among other Indian companies. Several drugs are expected to come off patent in this segment in the next five years.
PATENTLY ABSURD Latha Jishnu / New Delhi July 23, 2008, 0:26 IST Some extraordinary initiatives have been launched in recent times to ensure that the poorest of the world have access to medicines to fight pandemics and life-threatening diseases. One such is UNITAID, an international drug purchase facility that brings together 27 countries to help fight three killer diseases: HIV/AIDS, malaria and tuberculosis. The project was started by France, Brazil, Chile, Norway and the UK and its members are mostly African countries which are the worst victims of these afflictions.
Pb Jayakumar / Mumbai July 18, 2008, 0:40 IST US-based Abbot Laboratories has filed a suit against Dr Reddy's Laboratories for infringing the patent of Depakote ER, an anti-seizure or epilepsy drug with sales of over $1.48 billion (more than s 6,000 crore) in the American market.
The Ranbaxy sale to Daiichi Sankyo could herald a new phase in the evolution of the Indain pharmaceutical industry. In order to cope in a world after the agreement on Trade-related Aspects of Intellectual Property Rights came into force, some of the larger Indian firms pursued the two strategies of a greater internationalisation of sales of generic drugs and a focus on research and development as junior partners of global giants. Ranbaxy had mixed success with the two strategies.
Exide Industries Ltd has jointly applied for a global patent for an
Today's world trade volume is 27 times that of 1950. Trade liberalisation has made no small contribution to global warming due to spectacular growth in the transportation industry. Today, when they need to negotiate the climate regime to replace the Kyoto Protocol after 2012, industrial and developing countries bicker over what would constitute more climate-friendly trade rules.
SUN Pharmaceutical Industries, the country's most valuable drugmaker, has decided to launch a hostile bid for Israel's Taro Pharmaceutical Industries. This is a rare instance of an Indian company making an unsolicited bid for a foreign firm. The move follows Taro's rejection of a merger agreement with Sun last month. Taro had termed the offer